Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2005-08-30
2005-08-30
Nolan, Patrick J. (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S139100, C435S007100, C435S007200, C435S007210, C435S007240, C435S029000
Reexamination Certificate
active
06936248
ABSTRACT:
The invention relates to an antibody or antigen-binding fragment thereof which binds to the CC chemokine receptor GPR-9-6 and blocks the binding of a ligand (e.g., TECK) to the receptor. The invention also relates to a method of identifying agents (molecules, compounds) which can bind to GPR-9-6 and inhibit the binding of a ligand (e.g., TECK) and/or modulate a function of GPR-9-6. The invention further relates to a method of modulating a function of GPR-9-6, and to the use of the antibodies, antigen-binding fragments and agents identified by the method of the invention in research, therapeutic, prophylactic and diagnostic methods.
REFERENCES:
patent: 5440021 (1995-08-01), Chuntharapai et al.
patent: 5652133 (1997-07-01), Murphy
patent: 6329159 (2001-12-01), Andrew et al.
patent: 6503735 (2003-01-01), Wei et al.
patent: WO 97/48807 (1997-12-01), None
patent: WO 98/01557 (1998-01-01), None
patent: WO 98/32858 (1998-07-01), None
Huang Pharmacol. Therapeutics 2000 86:201-215.
Zlotnik and Yoshie Immunity 2000;12:121-127.
Mackay Nature Immunol. 2001;2:95-101.
ATCC Accession No. CRL-1582, ATCC Cell Lines and Hybridomas, p. 149, 7th edition, 1992, American Type Culture Collection, current address 10801 University Boulevard, Manassas, VA 20110-2209.
MOLT-13, ACC 436, [online] Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, 2003 [retrieved on Mar. 4, 2003]. Retrieved from the Internet: <URL: www.dsmz.de/dsmzhome.htm.
Nibbs, R.J.B., et al., “Cloning and Characterization of a Novel Promiscuous Human β-Chemokine Receptor D6,”J. Biol Chem., 272(51):32078-32083 (1997).
Murphy, P.M., et al., “Internatianal Union of Pharmacology. XXII. Nomenclature for Chemokine Receptors,”Pharmacol. Rev., 52(1):145-176 (2000).
Youn, B-S, et al., “TECK, an Efficacious Chemoattractant for Human Thymocytes, Uses GPR-9-6/CCR9 as a Specific Receptor,”Blood, 94(7) :2533-2536 (1999).
Attwppd. T.K., “The Babel of Bioinformatics,”Science, 290:471-473 (2000).
Yoshida, R., et al., “Molecular Cloning of a Novel Human CC Chemokine EBI1-ligand Chemokine That is a Specific Functional Ligand for EBI1, CCR7,”The Journal of Biological Chemistry, 272(21):13803-13809 (1997).
Baba, M., et al., “Identification of CCR6, the Specific Receptor for a Novel Lymphocyte-directed CC Chemokine LARC,”The Journal of Biological Chemistry, 272(23):14893-14898 (1997).
Imai, T., et al., “The T Cell-directed CC Chemokine TARC is a Highly Specific Biological Ligand for CC Chemokine Receptor 4,”The Journal of Biological Chemistry, 272(23):15036-15042 (1997).
Kitaura, M., et al., “Molecular Cloning of Human Eotaxin, an Eosinophil-selective CC Chemokine, and Identification of a Specific Eospinophil Eotaxin Receptor, CC Chemokine Receptor 3,”The Journal of Biological Chemistry, 271(13):7725-7730 (1996).
Vicari, A.P., et al., “TECK: A Novel CC Chemokine Specifically Expressed by Thymic Dendritic Cells and Potentially Involved in T Cell Development,”Immunity, 7291-301 (1997).
Damon, I., et al., “Broad Spectrum Chemokine Antagonistic Activity of a Human Poxvirus Chemiline Homolog,”Proc. Natl. Acad. Sci. USA, 95:6403-6407 (1998).
O'Garra, A., et al., “T-cell Subsets: Chemikine Receptors Guide the Way,”Current Biology, 8:R646-R649 (1998).
Kim, C.H., et al., “Chemokines: Signal Lamps for Trafficking of T and B Cells for Development and Effector Function,”J. Leukoc. Biol., 65:6-15 (1999).
Murphy, P.M., “The Molecular Biology of Leukocyte Chemoattractant Receptors,”Annu. Rev. Immunol., 12:593-633 (1994).
Zlotnik, A., et al., “Recent Advances in Chemokines and Chemokine Receptors,”Critical Reviews™ in Immunology, 19:1-47 (1999).
Nomiyama, H., et al., “The Human CC Chemokine TECK (SCYA25) Maps to Chromosome 19p13.2,”Genomics, 51:311-312 (1998).
Vicari, A.P. et al., “TECK: A Novel CC Chemokine Associated with T-Cell Development,”J. Allergy Clin. Immunol., 99(1):S246, Abstract No. 1003, (1997).
Combadiere, C., et al., “Cloning and Functional Expression of Two Human CC Chemokine Receptors,”FASEB J. 10(6):A1093 Abstract No. 545, (1996).
Gao, J.-L., et al., “Cloning and Expression of the Mouse MIP-1α Receptor Gene and Two Related Genes,”9th International Congress of Immunology, p. 108, Abtsract No. 637 (1995).
GenBank Accession No. U45982, “Human G Protein Coupled Receptor GPR-9-6 Gene, Complete CDS,” (1996).
Zaballos, A., et al., “Cutting Edge: Identification of the Orphan Chemokine Receptor GPR-9-6 and CCR9, the Receptor for the Chemokine TECK,”J. Immunol., 162(10):5671-5675 (1999).
Chuntharapai, A. and Kim, K.J., “Generation of Monoclonal Antibodies to Chemokine Receptors,”Methods in Enzymology, 288:15-27 (1997).
Locati M. et al., “Chemokines and Chemokine Receptors: Biology and Clinical Relevance in Inflammation and AIDS,”Annu. Rev. Med. 50:425-440 (1999).
Zabel, B.A. et al., “Human G Protein-coupled Receptor GPR-9-6/CC Chemokine Recpeotr 9 is Selectively Expressed on Intestinal Homing T Lymphoctyes, Mucosal Lymphocytes, and Thymocytes and is Required for Thymus-expressed Chemokine-mediated Chemotaxis,”J. Exp. Med 1990(9):1241-1255 (1999).
Swissprot Database, Accession No.: P51686, “Probable G-Protein-Coupled Receptor GPR-9-6” [online], Oct. 1996.
Andrew David P.
Ponath Paul D.
Zabel Brain A.
Hamilton Brook Smith & Reynolds P.C.
Millennium Pharmaceuticals Inc.
Nolan Patrick J.
LandOfFree
Methods of inhibiting GPR-9-6 function does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of inhibiting GPR-9-6 function, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of inhibiting GPR-9-6 function will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3515708